R. Scott Peterson

About R. Scott Peterson

With over two decades of experience in biopharma, I lead enterprise asset strategy at AbbVie within the Plastics & Regenerative Medicine franchise. I am accountable for integrated development and commercialization strategy across assets spanning discovery through lifecycle optimization.I chair cross-functional governance forums that align clinical, regulatory, medical, operational and commercial functions around risk-adjusted portfolio decisions. My work centers on translating complex clinical and market data into structured decision architecture that drives capital-efficient execution and sustainable asset performance.My experience includes establishing governance frameworks, aligning global medical and commercial priorities, and guiding programs through major portfolio inflection points. Trained as a molecular physiologist, I bring scientific rigor to enterprise strategy, ensuring that data integrity and disciplined execution underpin long-term value creation in dermatology and regenerative medicine.

Experience

1. Asset Strategy Leader - Plastics & Regenerative Medicine

   AbbVie

   Feb 2024 — Present · CA, US

   Provide enterprise-wide matrix leadership for the Plastics & Regenerative Medicine franchise portfolio, accountable for assets from discovery through end-of-life. Lead cross-functional teams to execute global program strategy and launch multiple high-profile, multi-indication products across key markets, aligning franchise initiatives with enterprise portfolio priorities. • Chair Asset Strategy Teams (ASTs) to ensure alignment across five core deliverable areas: Integrated Evidence, Value & Access, Brand, Label & Regulatory, and Product Presentation. • Lead the creation and endorsement of an integrated cross-functional strategy covering all aspects of product development and commercialization; direct teams to navigate complex, emergent situations. • Cultivate strong peer-to-peer relationships with team members and executives, enabling timely, multidirectional communication through governance forums at key milestones and during critical program inflection points. • Leverage emerging data to guide AST recommendations that capitalize on opportunities, address risks, and implement proactive mitigations. • Ensure continuous validation of program viability from scientific and commercial perspectives. Define clear Go/No-Go decision points and act as a franchise champion, using sound judgment to analyze, interpret, and present data to executive leadership and board members.

Education

• The Johns Hopkins University

  Bachelor of Arts, Behavioral Biology

  1993 — 1997

• UCLA

  Master of Science, Physiological Science

  1997 — 1999

• UCLA

  Doctor of Philosophy, Molecular, Cellular & Integrative Physiology

  1999 — 2004

Skills

• Pharmacovigilance
• Molecular Biology
• Clinical Development
• Neuroscience
• Pharmaceutical Industry
• Pharmacology
• Drug Discovery
• Clinical Trials
• Medical Devices
• Clinical Research
• Kol Identification
• Multiple Sclerosis
• Molecular
• Medicine
• Cell
• Drug Development
• Gcp
• R&D
• Microscopy
• Biotechnology
• Research and Development (R&D)
• Endocrinology
• Dermatology
• Immunology
• Medical Writing
• Cell Biology
• Life Sciences
• Commercialization
• Histopathology
• Cardiology
• Publication Planning
• Regulatory Affairs
• Nanotechnology
• Lifesciences
• Protocol Design
• Protocol
• Business Development
• Neurology
• Medical Affairs
• Scientific Communications